» Articles » PMID: 29119463

Socio-demographic Profile and Economic Burden of Treatment of Transfusion Dependent Thalassemia

Overview
Specialty Pediatrics
Date 2017 Nov 10
PMID 29119463
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To compile the socio-demographic profile and estimate the economic burden of transfusion dependent thalassemia.

Methods: This cross-sectional descriptive study was conducted at a tertiary care hospital in north India. Transfusion dependent thalassemia patients on regular blood transfusion for at least a year were selected. Thalassemia diagnosis was based on HPLC and/or mutation analysis results. Clinical and laboratory parameters were collected from electronic health records. Information regarding socio-economic profile and costs incurred, including indirect costs were collected by interviewing patients' guardians. The data was analyzed as a whole cohort and also in subgroups based on age.

Results: The data of 261 patients with a median age of 127 mo was collected. The median age at diagnosis was 9.8 mo. The total treatment expenses of a patient per year ranged from US$ 629 (INR 41,514) to US$ 2300 (INR 151,800), in the different age groups, at an average of US$ 1135 (INR 74,948). More than half (53%) of this was spent on medications. On an average, 38.8% of the family income was spent on the treatment of a thalassemia patient annually. Only 19 of 262 cases had an average pre-BT Hb ≥ 9 g/dl and serum ferritin ≤1500 ng/dl.

Conclusions: The treatment for transfusion dependent thalassemia is costly and mostly borne by the families in India. This study provides a realistic magnitude of this burden and will be useful in planning a thalassemia management program at the state or national level.

Citing Articles

Systematic literature review of the indirect costs and humanistic burden of β-thalassemia.

Aydinok Y, Purushotham S, Yucel A, Glassberg M, Deshpande S, Potrata B Ther Adv Hematol. 2024; 15:20406207241270872.

PMID: 39297078 PMC: 11409307. DOI: 10.1177/20406207241270872.


Global Globin Network and adopting genomic variant database requirements for thalassemia.

Halim-Fikri H, Zulkipli N, Alauddin H, Bento C, Lederer C, Kountouris P Database (Oxford). 2024; 2024.

PMID: 39231257 PMC: 11373567. DOI: 10.1093/database/baae080.


Economic Evaluation of Nucleic Acid Testing for Screening of Blood Donations for Thalassemia Patients (ECONAT) in Western India.

Anne P, Gupta A, Misra S, Sharma S, Garg M, Bajpayee A Indian J Hematol Blood Transfus. 2023; 39(2):317-324.

PMID: 37006984 PMC: 10064373. DOI: 10.1007/s12288-022-01564-8.


Safety and Efficacy of Thalidomide and Hydroxyurea Combination in Beta Thalassemia Patients.

Garg A, Patel K, Shah K, Trivedi D, Raj A, Yadav R Indian J Hematol Blood Transfus. 2023; 39(1):85-89.

PMID: 36699430 PMC: 9868204. DOI: 10.1007/s12288-022-01536-y.


Healthcare resource utilization and direct costs of transfusion-dependent thalassemia patients in Dubai, United Arab Emirates: a retrospective cost-of-illness study.

Alshamsi S, Hamidi S, Narci H BMC Health Serv Res. 2022; 22(1):304.

PMID: 35248046 PMC: 8897869. DOI: 10.1186/s12913-022-07663-6.


References
1.
Scalone L, Mantovani L, Krol M, Rofail D, Ravera S, Bisconte M . Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin. 2008; 24(7):1905-17. DOI: 10.1185/03007990802160834. View

2.
Amid A, Saliba A, Taher A, Klaassen R . Thalassaemia in children: from quality of care to quality of life. Arch Dis Child. 2015; 100(11):1051-7. DOI: 10.1136/archdischild-2014-308112. View

3.
Mallik S, Chatterjee C, Mandal P, Sardar J, Ghosh P, Manna N . Expenditure to treat thalassaemia: an experience at a tertiary care hospital in India. Iran J Public Health. 2012; 39(1):78-84. PMC: 3468966. View

4.
Verma I, Saxena R, Kohli S . Past, present & future scenario of thalassaemic care & control in India. Indian J Med Res. 2011; 134:507-21. PMC: 3237251. View

5.
Sangani B, SUKUMARAN P, Mahadik C, Yagnik H, Telang S, Vas F . Thalassemia in Bombay: the role of medical genetics in developing countries. Bull World Health Organ. 1990; 68(1):75-81. PMC: 2393015. View